GlassScriptPhysician profile
Vaseem Ali
NPI 1487689378
$5,540.15
in general payments reported to CMS, 2019-2025
37 companies · $565 in 2025
The $565 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $734 · 2021: $845 · 2022: $1,042 · 2023: $1,027 · 2024: $579 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $752.53 | 2020-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Coroflow, Cardiomems |
| Boston Scientific Corporation | $634.51 | 2019-2024 | Watchman Flx, Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Abbvie INC. | $463.01 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $444.56 | 2020-2024 | Xarelto |
| Amgen INC. | $318.48 | 2019-2025 | Repatha, Evenity |
| Novo Nordisk INC | $302.27 | 2021-2025 | Wegovy, Ozempic |
| Coloplast Corp | $278.52 | 2019-2021 | |
| Akcea Therapeutics, INC. | $250.03 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $243.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $226.55 | 2021-2025 | Verquvo, Belsomra |
| Cleerly, INC. | $174.89 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
| Caldera Medical, INC | $161.94 | 2023 | Desara |
| Esperion Therapeutics, INC. | $153.26 | 2020-2022 | |
| Astellas Pharma US INC | $116.01 | 2021-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.09 | 2019-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vaseem Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.